Michael Gelband’s XBiotech XBIT Stock Holding History

Michael Gelband’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,177	Closed	-$132K	–	2046
2024 Q1	$132K	Buy	+16,177	New	+$92.7K	﹤0.01%	1404
2021 Q2	–	Sell	-12,811	Closed	-$220K	–	2870
2021 Q1	$220K	Buy	+12,811	New	+$239K	﹤0.01%	1836
2019 Q2	–	Sell	-53,560	Closed	-$590K	–	1356
2019 Q1	$590K	Buy	+53,560	New	+$434K	0.04%	284

Other funds holding XBIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Michael Gelband's XBIT Position: Q2 2024 in Review

Michael Gelband sold out of XBiotech (XBIT) in Q2 2024, closing a stake of 16,177 shares — an estimated $132K sold.

Michael Gelband first reported a position in XBIT in Q1 2019 and held it in 3 quarters. The position peaked at $590K in Q1 2019. 46 funds tracked by Wall St. Rank hold XBIT as of Q2 2024.

Michael Gelband reported no remaining XBiotech position as of Q2 2024 after selling out during the quarter.
Michael Gelband sold 16,177 XBiotech shares in Q2 2024, an estimated $132K.
Michael Gelband first reported a position in XBiotech in Q1 2019 and held it in 3 quarters.
Michael Gelband's XBiotech position peaked at $590K in Q1 2019.
46 funds tracked by Wall St. Rank held XBiotech as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.